Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 125

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 125
---
, 2023). According to our distributor this is due to greater interest in treating babesiosis. 72 Service Revenues During the nine months ended September 30, 2024, we recognized $10,789 in service revenue in association with the final payment from the USAMMDA for storing Arakoda purchases ($0 for the nine months ended September 30, 2023). The revenue for the nine months ended September 30, 2024 is related to the final resolution of storage fees payable from the USAMMDA under the original development contract entered into in 2014. As the development contract ended on August 31, 2022, additional storage revenue is not expected in the near future. Cost of Revenues, Gross Profit (Loss), and Gross Margin Cost of revenues was $266,688 for the nine months ended September 30, 2024, as compared to $328,293 for the nine months ended September 30, 2023. While net product sales increased over the same periods, the decrease in cost of goods sold is primarily attributable to the fixed part of cost of goods. As the sales volume has increased, the gross margin has improved as the variable cost of goods of each unit sold is substantially less than the sales price. Additionally, write-downs for expired inventory were significantly higher during the nine months ended September 30, 2023 at $94,977, as compared to $18,490 during the nine months ended September 30, 2024. Due to these factors, the Gross Margin % increased significantly from (156.70%) for the nine months ended September 30, 2023 to 29.21% for the nine months ended September 30, 2024. Other Operating Revenues

|                   | Consolidated Statements of Operations Data: | Nine Months Ended 
 September 30,     |   2024 |     |   |   2023 |     |   | $ Change |   |     |     | % Change |    |
|:------------------|:--------------------------------------------|:------------------|-------:|:----|:--|-------:|:----|:--|:---------|:--|:----|:----|:---------|:---|
| Research Revenues |                                             | $                 | 43,177 |     | $ | 82,974 |     | $ | (39,797  | ) |     |     | (47.96   | )%